Diamines Q1 FY27: consolidated loss narrows to ₹0.1 Cr YoY as standalone swings to profit
PAT +96.33% YoY · revenue +17.31% · margins expanding
₹14.37 Cr
+17.31% YoY
₹-0.1 Cr
+96.33% YoY
-0.69%
+19.2pp YoY
₹-0.1
Diamines & Chemicals reported consolidated revenue of ₹14.37 Cr for Q1 FY27 (quarter ended June 30, 2026), up 17.3% YoY from ₹12.25 Cr and up 54.8% QoQ from ₹9.29 Cr (the March quarter is seasonally softer for this specialty-chemicals business). The consolidated net loss narrowed sharply to ₹0.10 Cr from a ₹2.81 Cr loss a year ago (-96.3% YoY) and a ₹2.42 Cr loss last quarter (-95.7% QoQ); consolidated PBT was a marginal ₹-0.05 Cr versus ₹-2.96 Cr YoY, effectively a break-even quarter at the operating level.
Q1 FY-2027 vs prior quarters
The consolidated and standalone numbers diverge in sign this quarter: standalone (parent-only) swung to a ₹0.27 Cr profit (EPS ₹0.27) from a ₹2.39 Cr loss YoY, while the consolidated entity stayed marginally loss-making. The gap between the two is entirely attributable to the wholly-owned subsidiary DACL Fine Chem, which posted a ₹0.34 Cr net loss this quarter, plus a further ₹0.056 Cr share-of-loss from associate KLJ Organics Diamines — both drags layered on an otherwise-profitable parent. At the standalone level, the swing to profit was driven mainly by Other Expenses falling to ₹3.83 Cr from ₹7.85 Cr YoY (-51.2%), even as Cost of Materials Consumed rose 21.4% to ₹7.83 Cr (slightly ahead of the 17.5% standalone revenue growth) — cost discipline on the other-expenses line more than offset a modest rise in material-cost intensity.
The stock went into the print at ₹272, up 0.4% over the past month of trading.
For context: PAT has now risen for 3 consecutive quarters.
No formal revenue or profit guidance is on record for this company — management's board disclosure for this result focuses on capex and corporate-structure items rather than quantitative outlook, so the quarter cannot be graded against a prior guide (vsGuidance: unknown). No analyst consensus or street preview could be identified either, consistent with the company's scale (~₹14 Cr quarterly consolidated revenue sits outside typical brokerage coverage). Two board actions tie directly to the numbers: the board approved an additional ₹40 Cr investment into DACL Fine Chem (via loan/debenture/equity) to fund the new chemical plant, which management says has reached substantial mechanical and commissioning completion but has not yet started commercial production pending optimization of the downstream distillation process — the likely source of the subsidiary's ongoing losses. Separately, the board discontinued the long-dormant Trading Division (Fruits & Vegetables segment), which had zero revenue since last year and had contributed a ₹3.58 Cr segment loss in FY26; its removal should simplify segment reporting going forward with no income-statement impact this quarter.
W1
Commercial production start date for the new chemical plant, currently pending downstream distillation-process optimization (per Aug 5, 2026 board update)
W2
Trajectory of DACL Fine Chem subsidiary losses (₹0.34 Cr this quarter) as the ₹40 Cr additional investment is deployed
W3
Whether consolidated PAT turns positive next quarter, given the loss narrowed to just ₹0.10 Cr this quarter from ₹2.81 Cr a year ago
Consolidated PAT (₹-0.1033 Cr) includes a ₹0.0557 Cr share-of-loss from associate KLJ Organics Diamines below the PBT-tax line (PAT≠PBT-tax directly); standalone PBT-tax ties out exactly to PAT. Standalone (+₹0.27 Cr) and consolidated (-₹0.10 Cr) diverge in sign this quarter due to subsidiary DACL Fine Chem loss and associate share. Source figures in ₹ Lakhs, converted to Crore; scans are clear with minor OCR noise on table borders (verified against printed totals).